Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Luigi M. Barbato"'
Autor:
Sun Ju Chung, Matilde Calopa, Maria G. Ceravolo, Nicola Tambasco, Angelo Antonini, K. Ray Chaudhuri, Weining Z. Robieson, Olga Sánchez-Soliño, Cindy Zadikoff, Man Jin, Luigi M. Barbato
Publikováno v:
Parkinson's Disease, Vol 2022 (2022)
Background. Nonmotor symptoms (NMS) are common in advanced Parkinson’s disease (APD) and reduce health-related quality of life. Objective. The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatm
Externí odkaz:
https://doaj.org/article/a578f099bea44185813cc8cb510cafe0
Autor:
Eero Pekkonen, Egon Kurča, P. Vanni, Eric Freire-Alvarez, Luigi M Barbato, Cleanthe Spanaki, Yang Liu, Olga Sanchez-Soliño, Lydia Lopez Manzanares
Publikováno v:
Movement Disorders. 36:2615-2623
BACKGROUND There are limited data regarding the effectiveness of levodopa-carbidopa intestinal gel (LCIG) for dyskinesia. OBJECTIVE Compare the effectiveness of LCIG versus oral optimized medical treatment (OMT) for dyskinesia in patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc188a599412bea69083bac704b8f5e0
https://doi.org/10.1002/mds.28703
https://doi.org/10.1002/mds.28703
Autor:
D. Haichen Yang, James Schmeidler, Lorrin M. Koran, Eric Hollander, Luigi M. Barbato, Alicia Kaplan, David Li
Publikováno v:
The Journal of Neuropsychiatry and Clinical Neurosciences. 17:472-477
Neurological soft-sign abnormalities have been implicated in obsessive-compulsive disorder (OCD). This first comprehensive data analysis evaluated the association between baseline neurological soft signs and treatment response in 117 OCD patients tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c26653c250ff28feec0bb135250b11
https://doi.org/10.1176/jnp.17.4.472
https://doi.org/10.1176/jnp.17.4.472
Autor:
David Li, Roland Gerritsen van der Hoop, Loretta Stallings, Robert I. Dupont, Jose Yaryura-Tobias, Jonathan R. T. Davidson, Luigi M. Barbato
Publikováno v:
Journal of Clinical Psychopharmacology. 24:118-125
Generalized social anxiety disorder is a highly prevalent anxiety disorder with deleterious effects on social and family relationships, as well as work performance. We report the results of a multicenter, randomized, placebo-controlled trial comparin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb3f82ad43d1a6d7804980db90033e8
https://doi.org/10.1097/01.jcp.0000106222.36344.96
https://doi.org/10.1097/01.jcp.0000106222.36344.96
Publikováno v:
The International Journal of Neuropsychopharmacology. 6:317-323
Fluvoxamine CR has been reported effective in the short-term (12-wk) treatment of generalized social anxiety disorder (social phobia). Social anxiety disorder (SAD) is, however, a chronic disorder thought to require maintenance treatment. We report o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a77da663d868334122928048ac250c49
https://doi.org/10.1017/s146114570300364x
https://doi.org/10.1017/s146114570300364x
Autor:
Wayne K. Goodman, Haichen Yang, Eric Hollander, Luigi M. Barbato, Lorrin M. Koran, David Li, Philip T. Ninan, John H. Greist
Publikováno v:
The Journal of Clinical Psychiatry. 64:640-647
OBJECTIVE: The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallel-arm, multicenter trial was to determine the safety and efficacy of fluvoxamine in a controlled-release (CR) formulation in adult outpatients with obsessive-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3604d00bd16bf3a3ce47be2b9586f9
https://doi.org/10.4088/jcp.v64n0604
https://doi.org/10.4088/jcp.v64n0604
Autor:
Luigi M. Barbato, Haresh S. Jhangiani, Vickie Baranowski, Eyal Meiri, James J. Vredenburgh, Frederick J. Carter, Hwa-Ming Yang
Publikováno v:
Current medical research and opinion. 23(3)
To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study.Patients receiving moderately to highly emetogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f1fe3f542f0cda08c13c7be2862414
https://pubmed.ncbi.nlm.nih.gov/17355735
https://pubmed.ncbi.nlm.nih.gov/17355735
Autor:
Eyal Meiri, Haresh Jhangiani, James J. Vredenburgh, Luigi M. Barbato, Frederick J. Carter, Hwa-Ming Yang, Vickie Baranowski
Publikováno v:
Current Medical Research & Opinion; Mar2007, Vol. 23 Issue 3, p533-543, 11p